238 related articles for article (PubMed ID: 32418256)
1. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
3. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: practice patterns across Europe.
Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
[TBL] [Abstract][Full Text] [Related]
5. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
Weisel K; Wadlund AO; Gungor G; Dergarabetian E; Pacheco C; Masurkar N; Rodriguez-Otero P
Eur J Haematol; 2022 Oct; 109(4):388-397. PubMed ID: 35775385
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
7. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Hari P; Blazer M; Raju A; Farrelly E; Labotka R; Skacel T; Romanus D
Expert Rev Hematol; 2019 Jan; 12(1):71-79. PubMed ID: 30513016
[TBL] [Abstract][Full Text] [Related]
8. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
[TBL] [Abstract][Full Text] [Related]
9. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant.
Ailawadhi S; Ogbonnaya A; Murty S; Cherepanov D; Schroader BK; Romanus D; Farrelly E; Chari A
Cancer Med; 2023 Feb; 12(3):3145-3159. PubMed ID: 36151787
[TBL] [Abstract][Full Text] [Related]
10. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Mohty M; Cavo M; Fink L; Gonzalez-McQuire S; Leleu H; Mateos MV; Raab MS; Schoen P; Yong K
Eur J Haematol; 2019 Aug; 103(2):107-115. PubMed ID: 31112311
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: patient outcomes in real-world practice.
Yong K; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Raab MS; Schoen P; Cavo M
Br J Haematol; 2016 Oct; 175(2):252-264. PubMed ID: 27411022
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
14. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
15. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
16. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
17. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.
Weil C; Gelerstein S; Sharman Moser S; Chodick G; Barit Ben-David N; Shalev V; Shofaniyeh I; Kamalov R; Meytes D
Leuk Res; 2019 Oct; 85():106219. PubMed ID: 31473468
[TBL] [Abstract][Full Text] [Related]
18. Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019.
Schjesvold F
Eur J Haematol; 2020 Oct; 105(4):434-448. PubMed ID: 32557833
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P; Romanus D; Palumbo A; Luptakova K; Rifkin RM; Tran LM; Raju A; Farrelly E; Noga SJ; Blazer M; Chari A
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):152-160. PubMed ID: 29395837
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
